Distribution of HPV Genotypes in Patients with a Diagnosis of Anal Cancer in an Italian Region

Objectives: Anal cancer is a rare disease. However, its incidence is increasing in some population groups. Infection caused by Human Papillomavirus (HPV) is strongly associated with the risk of anal cancer, whose variability depends on samples, histology, and HPV detection methods. The aim of the study was to assess prevalence and distribution of HPV genotypes in patients diagnosed with anal carcinoma. Methods: An observational, retrospective study was carried out in a tertiary care hospital in North Sardinia, Italy. Specimens of anal cancer diagnosed from 2002–2018 were selected. Demographic, epidemiological, and clinical variables were collected to assess their relationship with the occurrence of anal cancer. Results: The overall HPV positivity was 70.0% (21/30), with HPV-16 being the predominant genotype (~85%). The highest prevalence of anal cancer was in patients aged ≥55 years. HPV positivity was higher in women (p-value > 0.05) and in moderately differentiated samples (G2) (p-value < 0.05). p16INK4a and E6-transcript positivity were found in 57% and 24% of the HPV positive samples, respectively. The OS (overall survival) showed a not statistically significant difference in prognosis between HPV positive sand negatives (10, 47.6%, vs. 4, 44.4%; p-value = 0.25). Conclusions: HPV-DNA and p16INK4a positivity confirmed the role of HPV in anal carcinoma. Our findings could support the implementation and scale-up of HPV vaccination in males and females to decrease the incidence of HPV-associated cancers. Further studies are needed to better clarify the prognostic role of HPV/p16 status.

[1]  M. Thomas,et al.  A Systematic Review and Meta-Analysis of Prognostic Biomarkers in Anal Squamous Cell Carcinoma Treated With Primary Chemoradiotherapy. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[2]  A. Wald,et al.  Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA) , 2019, JAMA network open.

[3]  K. Canfell,et al.  Anal cancer in high-income countries: Increasing burden of disease , 2018, PloS one.

[4]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[5]  E. Boccardo,et al.  Alterations in the expression and activity of extracellular matrix components in HPV-associated infections and diseases , 2018, Clinics.

[6]  S. Klug,et al.  Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review , 2018, BMC Medicine.

[7]  N. Wentzensen,et al.  Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta‐analysis of cytology, HPV testing, and other biomarkers , 2018, Cancer cytopathology.

[8]  N. Hacker,et al.  Vulvar cancer in high‐income countries: Increasing burden of disease , 2017, International journal of cancer.

[9]  S. Franceschi,et al.  Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis , 2017, The Lancet. Infectious diseases.

[10]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[11]  J. Hofmann,et al.  Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations. , 2017, Oncology letters.

[12]  S. Devesa,et al.  Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and Behavior , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[13]  M. Tommasino,et al.  Role of human papillomaviruses in carcinogenesis , 2015, Ecancermedicalscience.

[14]  G. Sotgiu,et al.  HPV infection and triple-negative breast cancers: an Italian case-control study , 2014, Virology Journal.

[15]  P. Ravenda,et al.  Prognostic value of human papillomavirus in anal squamous cell carcinoma , 2014, Cancer Chemotherapy and Pharmacology.

[16]  S. Garland,et al.  Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers , 2014, International journal of cancer.

[17]  D. Templeton,et al.  The epidemiology of anal cancer. , 2012, Sexual health.

[18]  L. Murray,et al.  Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. , 2012, Oral oncology.

[19]  C. Abnet,et al.  Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: Results from the FINBAR study , 2012, International journal of cancer.

[20]  L. Siproudhis,et al.  Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study , 2011, International journal of cancer.

[21]  J. Palefsky,et al.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions , 2009, International journal of cancer.

[22]  Melanie A. Williams,et al.  Understanding the burden of human papillomavirus‐associated anal cancers in the US , 2008, Cancer.

[23]  P. Porter,et al.  Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer , 2004, Cancer.

[24]  M. Frisch On the etiology of anal squamous carcinoma. , 2002, Danish medical bulletin.

[25]  K. Sotlar,et al.  Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. , 1998, Gynecologic oncology.

[26]  S. J. Henley,et al.  Five‐year relative survival for human papillomavirus‐associated cancer sites , 2018, Cancer.

[27]  S. De Flora,et al.  Incidence of infection-associated cancers in Italy and prevention strategies. , 2015, Epidemiologia e prevenzione.

[28]  M. Poljak,et al.  Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide , 2015, International journal of cancer.

[29]  L. Richiardi,et al.  Incidence of infection-associated cancers in Italy and prevention strategies. , 2015 .